On Dec. 19, 2025, Novartis, a leading global innovative medicines company, announced it has reached an agreement with the US government that aims to lower the price of innovative medicines in the US and support continued US investment in manufacturing, and research and development.

Novartis has voluntarily agreed to take actions aimed at meeting the US Administration’s drug pricing priorities, including: Launching future medicines with comparable prices across high-income countries; Supporting efforts to address the global imbalance in investment in pharmaceutical innovation; Building direct-to-patient platforms for Mayzent^® (siponimod), Rydapt^® (midostaurin) and Tabrecta^® (capmatinib), and Applying to participate in the GENEROUS (GENErating cost Reductions or U.S. Medicaid) Model aimed at further improving access to medicines in the US Medicaid program.

Earlier this year, Novartis committed to investing $23 billion in expanding its US R&D and manufacturing infrastructure over 5 years.